

Product Update

magnesium aspartate dihydrate equivalent to 243mg (10mmol) of
magnesium powder for oral solution (Magnaspartate[®])

SMC No. (1042/15)

Kora Corporation Limited

6 March 2015 (Issued 05 June 2015)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

magnesium aspartate dihydrate (Magnaspartate[®]) is accepted for use within NHS Scotland.

Indication under review: for the treatment and prevention of magnesium deficiency, as diagnosed by a doctor

This is the first licensed oral magnesium product to be available in the UK for the treatment and prevention of magnesium deficiency. Magnesium supplementation has previously been available as a food supplement.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 15 January 2015.

**Chairman,
Scottish Medicines Consortium**